CSIMarket
 


Trinity Biotech Plc  (TRIB)
Other Ticker:  
 
 

TRIB's Net Income Growth by Quarter and Year

Trinity Biotech Plc's Net Income results by quarter and year




TRIB Net Income (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December -41.00 0.93 -6.01 -28.99
III Quarter September 0.00 0.00 0.00 0.00
II Quarter June 0.00 0.00 0.00 0.00
I Quarter March 0.00 0.00 0.00 0.00
FY   -41.00 0.93 -6.01 -28.99



TRIB Net Income fourth quarter 2022 Y/Y Growth Comment
Trinity Biotech Plc in the fourth quarter 2022 recorded net loss of $ -41.00 millions.

According to the results reported in the fourth quarter 2022, Trinity Biotech Plc achieved the best Net Income growth in In Vitro & In Vivo Diagnostic Substances industry. While Trinity Biotech Plc' s Net Income no change of % ranks overall at the positon no. in the fourth quarter 2022.




TRIB Net Income ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Trinity Biotech Plc's fourth quarter 2022 Net Income $ -41.00 millions TRIB's Income Statement
Trinity Biotech Plc's fourth quarter 2021 Net Income $ 0.93 millions Quarterly TRIB's Income Statement
New: More TRIB's historic Net Income Growth >>


TRIB Net Income (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Net Income fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Income fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Trinity Biotech Plc's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


TRIB's IV. Quarter Q/Q Net Income Comment


Net Income Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


TRIB's IV. Quarter Q/Q Net Income Comment


Trinity Biotech Plc's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Dec 31 2022)
12 Months Ending
0
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
Cumulative Net Income 12 Months Ending $ -41.00 $ 0.00 $ 0.93 $ 0.00 $ 0.00
Y / Y Net Income Growth (TTM) - - - - -
Year on Year Net Income Growth Overall Ranking # # # # #
Seqeuential Net Income Change (TTM) - - - - -
Seq. Net Income Growth (TTM) Overall Ranking # # # # #




Cumulative Net Income growth Comment
Trinity Biotech Plc realized trailing twelve months net loss of $ -41 millions, in the Dec 31 2022, compare to Net Income of $ 1 millions a year ago.

Trinity Biotech Plc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Income growth Comment
Trinity Biotech Plc realized trailing twelve months net loss of $ -41 millions, in the Dec 31 2022, compare to Net Income of $ 1 millions a year ago.

Trinity Biotech Plc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Income Growth
In Vitro & In Vivo Diagnostic Substances Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
TRIB's Net Income Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for TRIB's Competitors
Net Income Growth for Trinity Biotech Plc's Suppliers
Net Income Growth for TRIB's Customers

You may also want to know
TRIB's Annual Growth Rates TRIB's Profitability Ratios TRIB's Asset Turnover Ratio TRIB's Dividend Growth
TRIB's Roe TRIB's Valuation Ratios TRIB's Financial Strength Ratios TRIB's Dividend Payout Ratio
TRIB's Roa TRIB's Inventory Turnover Ratio TRIB's Growth Rates TRIB's Dividend Comparisons



Companies with similar Net Income no change for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Net Income for the quarter ending Dec 31 2022
Halozyme Therapeutics Inc -1.29%$ -1.293 millions
Inmode Ltd -2.15%$ -2.153 millions
Vanda Pharmaceuticals Inc -3.07%$ -3.066 millions
Pro dex Inc -4.97%$ -4.973 millions
Iradimed Corporation-5.63%$ -5.627 millions
Polypid Ltd -7.15%$ -7.145 millions
Amedisys Inc -7.24%$ -7.245 millions
Biontech Se-8.34%$ -8.337 millions
Lemaitre Vascular Inc -8.87%$ -8.874 millions
Alcon inc -10.90%$ -10.904 millions
Acadia Healthcare Company Inc -11.71%$ -11.709 millions
Intuitive Surgical Inc -12.02%$ -12.020 millions
Eton Pharmaceuticals Inc -12.22%$ -12.223 millions
Steris Plc-13.82%$ -13.815 millions
Envista Holdings Corporation-14.34%$ -14.336 millions
Pharming Group N v -14.52%$ -14.516 millions
Bristol myers Squibb Company-14.63%$ -14.629 millions
Amgen Inc -14.90%$ -14.903 millions
Stryker Corp-14.95%$ -14.955 millions
Exagen Inc -15.49%$ -15.489 millions
Zynex inc -16.21%$ -16.213 millions
Uniqure N v -17.07%$ -17.069 millions
Qiagen N v -17.44%$ -17.438 millions
Merck and Co Inc -19.90%$ -19.899 millions
Chemed Corporation-21.27%$ -21.266 millions
Rapid Micro Biosystems Inc -22.31%$ -22.312 millions
Select Medical Holdings Corp-23.04%$ -23.037 millions
Baxter International Inc -23.55%$ -23.554 millions
Integer Holdings Corporation-23.84%$ -23.843 millions
Becton Dickinson And Company-24.93%$ -24.926 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com